European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment
Abstract
Background Outside clinical trials, data on systemic reactions (SRs) due to allergen immunotherapy (AIT) are scarce. Methods A prospective, longitudinal, web‐based survey of ‘real‐life’ respiratory allergen immunotherapy (AIT) clinical practice was conducted in France, Germany and Spain. SRs were recorded and coded according to the Medical Dictionary for Regulatory Activities (MedDRA) and risk factors associated with SRs were identified. Results A total of 4316 patients (corresponding to 4363 ongoing courses of AIT) were included. A total of 109 SRs were recorded, and 90 patients (2.1%) presented at least one SR. Most of the SRs occurred in subcutaneous allergen immunotherapy (SCIT) (89%, n = 97). The most frequently reported symptoms were urticaria, rhinitis, dyspnoea and cough. Respiratory symptoms appeared before skin symptoms. Most SRs occurred during the up‐dosing phase (75.8%) and were mild in severity (71.6%). Intramuscular adrenaline was administered in 17 SRs, but only 65% of these were subsequently classified as anaphylaxis. Independent risk factors for SRs during SCIT were as follows: the use of natural extracts (odds ratio, OR) [95% confidence interval (CI)] = 2.74 [1.61–4.87], P = 0.001), the absence of symptomatic allergy medications (1.707 [1.008–2.892], P = 0.047), asthma diagnosis (1.74 [1.05–2.88], P = 0.03), sensitization to animal dander (1.93 [1.21–3.09], P = 0.006) or pollen (1.16 [1.03–1.30], P = 0.012) and cluster regimens (vs rush) (4.18 [1.21–14.37], P = 0.023). A previous episode of anaphylaxis increased the risk for anaphylaxis in SCIT (OR [95% CI] = 17.35 [1.91–157.28], P = 0.01). Conclusion AIT for respiratory allergy is safe, with a low number of SRs observed in real‐life clinical practice. A personalized analysis of risk factors could be used to minimize SRs.Keywords
Funding Information
- European Academy of Allergy and Clinical Immunology
This publication has 33 references indexed in Scilit:
- International consensus on allergy immunotherapyJournal of Allergy and Clinical Immunology, 2015
- Adverse Events During Immunotherapy Against Grass Pollen‐Induced Allergic Rhinitis – Differences Between Subcutaneous and Sublingual TreatmentBasic & Clinical Pharmacology & Toxicology, 2015
- AAAAI/ACAAI Surveillance Study of Subcutaneous Immunotherapy, Years 2008-2012: An Update on Fatal and Nonfatal Systemic Allergic ReactionsThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus reportJournal of Allergy and Clinical Immunology, 2013
- Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyondJournal of Allergy and Clinical Immunology, 2011
- Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI Collaborative StudyAnnals of Allergy, Asthma & Immunology, 2010
- Allergen immunotherapy safety: Characterizing systemic reactions and identifying risk factorsAllergy and Asthma Proceedings, 2008
- Side‐effects of allergen‐specific immunotherapy. A prospective multi‐centre studyClinical & Experimental Allergy, 2006
- Evaluation of near-fatal reactions to allergen immunotherapy injectionsJournal of Allergy and Clinical Immunology, 2006
- Immunotherapy safety: a prospective multi‐centric monitoring study of biologically standardized therapeutic vaccines for allergic diseasesClinical & Experimental Allergy, 2004